Smith & Nephew plc (NYSE:SNN – Get Free Report) has been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company.
A number of analysts recently weighed in on SNN shares. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft started coverage on Smith & Nephew in a research note on Wednesday, July 24th. They issued a “buy” rating on the stock.
Read Our Latest Stock Report on SNN
Smith & Nephew Stock Performance
Institutional Trading of Smith & Nephew
Institutional investors have recently bought and sold shares of the company. Nomura Holdings Inc. purchased a new stake in Smith & Nephew during the fourth quarter worth $887,000. Lorne Steinberg Wealth Management Inc. boosted its position in Smith & Nephew by 53.6% during the second quarter. Lorne Steinberg Wealth Management Inc. now owns 231,045 shares of the medical equipment provider’s stock worth $5,725,000 after purchasing an additional 80,650 shares in the last quarter. Clearbridge Investments LLC purchased a new stake in Smith & Nephew during the first quarter worth $2,612,000. Tocqueville Asset Management L.P. boosted its position in Smith & Nephew by 294.9% during the first quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock worth $5,692,000 after purchasing an additional 167,599 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in Smith & Nephew by 355.8% during the second quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider’s stock worth $31,059,000 after purchasing an additional 964,762 shares in the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
- Five stocks we like better than Smith & Nephew
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- P/E Ratio Calculation: How to Assess Stocks
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Financial Services Stocks Investing
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.